==Womenswear retailer Reformation files for IPO

July 20 (Reuters) - Permira-backed womenswear retailer Reformation is targeting a valuation of up to $1 billion in its U.S. initial public offering, marking a rare ​public-market foray for a fashion brand in recent years.

The Vernon, California-based ‌company said on Monday it and some of its selling shareholders aim to raise up to $239.1 million in the IPO by offering 14.1 million shares priced between $15 and $17 each.

Name of issuer:	Reformation Inc.
Last filed shares:	14,062,500
Last filed price:	$15.00 - $17.00

Jersey Mike's Subs filed for an IPO

Jersey Mike's Subs and its existing investors have filed for an initial public offering (IPO) on the NYSE, targeting a valuation of up to $8 billion. The company aims to raise up to $1.09 billion by offering shares between $21.00 and $25.00 under the ticker symbol JMKE. 

• https://www.jerseymikes.com/ 

IPO Details

Expected Share Price: $21 to $25 per share
Ticker Symbol: JMKE
Listing Exchange: New York Stock Exchange (NYSE)
Target Capital Raised: Up to $1.09 billion (including secondary share sales from backers like Blackstone)
Underwriters: Morgan Stanley, Jefferies, and J.P. Morgan

Key Financials & Corporate Structure

Systemwide Sales: Hit $4.3 billion in 2025, marking a 13% increase.
Revenues & Profit: Reported net income of $55 million on $724 million in revenue.
Ownership Control: Private equity firm Blackstone (which bought a majority stake in early 2025) and existing stockholders are cashing out roughly 68% of the offering, but they will retain nearly two-thirds of the voting power post-IPO.

Latigo Biotherapeutics filed for an IPO

Latigo Biotherapeutics, a Thousand Oaks, California-based developer of non-opioid pain medicines, filed for an IPO with the SEC on July 17, 2026. The clinical-stage biotechnology company plans to raise $100 million and list on the Nasdaq under the ticker symbol LTGO. 

The Blue Owl Capital Inc.-backed clinical-stage developer of non-opioid pain medicines has one drug candidate in late-stage trials that has shown a roughly 50% greater analgesic effect than Vicodin, a comparable opioid, according to its filing Friday with the US Securities and Exchange Commission.

Key IPO Details

Ticker Symbol: LTGO
Target Exchange: Nasdaq Global Select Market
Underwriters: Goldman Sachs, Jefferies, Leerink Partners, and Guggenheim Securities
Target Amount: Approximately $100 million
Pipeline Highlights: The company is advancing LTG-001 (for acute pain) and LTG-321 (for osteoarthritis). Their lead candidate has shown a roughly 50% greater analgesic effect compared to the opioid Vicodin in trials.